World News | Israeli Startup's Personalised Cell Therapy Gets FDA Fast-track Designation

Jerusalem [Israel], December 22 (ANI/TPS): Netanya-based biotechnology startup BioGenCell announced it has received the US Food and Drug Administration's Fast Track Designation for BGC101, a personalized cell therapy for severe Critical Limb Threatening Ischemia (CLTI).

CLTI is a life-threatening form of peripheral artery disease, usually occurring in the legs.

Also Read | PM Modi in Kuwait: Prime Minister Narendra Modi Accorded Guard of Honour at Bayan Palace (See Pics and Video).

Using its TRACT platform, BGC101 regenerates damaged tissue, offering hope to patients with no other treatment options. The milestone follows promising clinical results. BioGenCell recently completed Phase 2 trial enrollment across the US, Europe, and Israel. (ANI/TPS)

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)